GSK, IDRx
GSK is reportedly in negotiations about a $1bn deal to acquire IDRx and its targeted therapy for a form of rare gastrointestinal tumour. In a new white paper from the World Without Disease ...
In a report released on January 9, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a ...
Chandrima Sanyal Pfizer And GSK's RSV Vaccines Safety Labels Updated, FDA Adds Warning For Rare Neurological Disorder FDA updates safety labels for Pfizer's Abrysvo and GSK's Arexvy RSV vaccines ...
Shares of GSK PLC GSK inched down 0.69% to £13.74 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100 Index UKX falling 0.86% to 8,280.36.
GSK’s vaccine portfolio. GSK’s portfolio of more than 20 marketed vaccines, one of the industry’s broadest, protects people against diseases such as meningitis, shingles, polio, measles ...
GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP), a condition affecting 30 ...
GSK (GSK) announced that the US Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, for GSK5764227, GSK’227, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback